Experienced in Erythema Nodosum

Ori Elkayam

6 Weizmann St, 
Tel Aviv, TA, IL 
Experienced in Erythema Nodosum
6 Weizmann St, 
Tel Aviv, TA, IL 
OverviewLocationsClinical Research

Overview

Ori Elkayam practices in Tel Aviv, Israel. Mr. Elkayam is rated as an Experienced expert by MediFind in the treatment of Erythema Nodosum. His top areas of expertise are Psoriatic Arthritis, Arthritis, Psoriasis, Fibromyalgia, and Thrombectomy.

His clinical research consists of co-authoring 161 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Erythema Nodosum.

Gender
Male

Locations

6 Weizmann St, Tel Aviv, TA, Israel

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: July 22, 2025
Intervention Type: Drug
Study Drugs: Baricitinib, TNF Inhibitor
Study Phase: Phase 4
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: June 13, 2022
Intervention Type: Drug
Study Phase: Phase 3
Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy and Safety of Intra-articular Injection of RegenoGel-OSP and RegenoGel as a Treatment of Osteoarthritis (OA)
Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy and Safety of Intra-articular Injection of RegenoGel-OSP and RegenoGel as a Treatment of Osteoarthritis (OA)
Enrollment Status: Completed
Publish Date: September 24, 2021
Intervention Type: Device
Study Phase: Not Applicable
View 2 Less Clinical Trials

161 Total Publications

The potency of cell-based assays to predict response to TNF inhibitor therapy.
The potency of cell-based assays to predict response to TNF inhibitor therapy.
Journal: Expert review of molecular diagnostics
Published: August 06, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Elkayam's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 58 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile